Načítá se...
Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
The Phosphoinositide-3-kinase (PI3K) pathway is often aberrantly activated in Estrogen Receptor positive (ER+) breast cancer and therapies combining PI3K inhibitors and anti-estrogens are under clinical development. Given that many PI3K inhibitors have substantial toxicities with continuous dosing a...
Uloženo v:
| Vydáno v: | Clin Cancer Res |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4946572/ https://ncbi.nlm.nih.gov/pubmed/26957555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0038 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|